Cargando…

Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer

INTRODUCTION: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of clinically aggressive tumors with high risk of recurrence and metastasis. Current pharmacological treatment options remain largely limited to chemotherapy. Despite promising results, the efficacy of immunotherapy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hossain, Fokhrul, Ucar, Deniz A., Monticone, Giulia, Ran, Yong, Majumder, Samarpan, Larter, Kristina, Luu, Hanh, Wyczechowska, Dorota, Heidari, Soroor, Xu, Keli, Shanthalingam, Sudarvili, Matossian, Margarite, Xi, Yaguang, Burow, Matthew, Collins-Burow, Bridgette, Del Valle, Luis, Hicks, Chindo, Zabaleta, Jovanny, Golde, Todd, Osborne, Barbara, Miele, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612326/ https://www.ncbi.nlm.nih.gov/pubmed/37901240 http://dx.doi.org/10.3389/fimmu.2023.1244159

Ejemplares similares

Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways
por: Hossain, Fokhrul, et al.
Publicado: (2018)

The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer
por: Vigolo, Michele, et al.
Publicado: (2023)

Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor
por: Chang, Tiffany C., et al.
Publicado: (2020)

Correction: Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor
por: Chang, Tiffany C., et al.
Publicado: (2021)

Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy
por: Dong, Shengli, et al.
Publicado: (2023)

Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models
por: Sabol, Rachel A., et al.
Publicado: (2019)

Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling
por: Bhatt, Akshita B., et al.
Publicado: (2021)

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment
por: Nguyen, Khoa, et al.
Publicado: (2021)

Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022)

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model
por: Matossian, Margarite D., et al.
Publicado: (2018)

Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells
por: Matossian, Margarite D., et al.
Publicado: (2021)

Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses
por: Hossain, Fokhrul, et al.
Publicado: (2018)

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes
por: Matossian, Margarite D., et al.
Publicado: (2017)

Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer
por: Bhatt, Akshita B., et al.
Publicado: (2021)

Quantifying Breast Cancer-Driven Fiber Alignment and Collagen Deposition in Primary Human Breast Tissue
por: Gurrala, Rakesh, et al.
Publicado: (2021)

γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
por: Ran, Yong, et al.
Publicado: (2017)

ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer
por: Hoang, Van T., et al.
Publicado: (2020)

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
por: Hossain, Fokhrul, et al.
Publicado: (2021)

Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer
por: Matossian, Margarite D., et al.
Publicado: (2021)

Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer
por: Matossian, Margarite D., et al.
Publicado: (2020)

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
por: Matossian, Margarite D., et al.
Publicado: (2019)

Liver Kinase B1 Regulates Remodeling of the Tumor Microenvironment in Triple-Negative Breast Cancer
por: King, Connor T., et al.
Publicado: (2022)

Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses
por: Monticone, Giulia, et al.
Publicado: (2022)

Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer
por: Hossain, Fokhrul, et al.
Publicado: (2021)

Obesity-Altered Adipose Stem Cells Promote ER(+) Breast Cancer Metastasis through Estrogen Independent Pathways
por: Sabol, Rachel A., et al.
Publicado: (2019)

γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
por: Lessard, Christian B., et al.
Publicado: (2020)

Leukotoxin of Bibersteinia trehalosi Contains a Unique Neutralizing Epitope, and a Non-Neutralizing Epitope Shared with Mannheimia haemolytica Leukotoxin
por: Murugananthan, Arumugam, et al.
Publicado: (2018)

β-Hemolysis May Not Be a Reliable Indicator of Leukotoxicity of Mannheimia haemolytica Isolates
por: Bavananthasivam, Jegarubee, et al.
Publicado: (2018)

CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells
por: Mitra, Ankita, et al.
Publicado: (2020)

GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies
por: Nguyen, Khoa, et al.
Publicado: (2022)

56371 The Signaling Axis of Tumor Suppressor LKB1 in Triple Negative Breast Cancer
por: Nguyen, Khoa, et al.
Publicado: (2021)

Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats
por: Madka, Venkateshwar, et al.
Publicado: (2023)

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
por: Guo, Shanchun, et al.
Publicado: (2018)

Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer
por: Zhao, Hongyou, et al.
Publicado: (2020)

Sulindac for stroke treatment: neuroprotective mechanism and therapy
por: Modi, Jigar Pravinchandra, et al.
Publicado: (2014)

Amine Containing Analogs of Sulindac for Cancer Prevention
por: Mathew, Bini, et al.
Publicado: (2018)

Oxazole and thiazole analogs of sulindac for cancer prevention
por: Mathew, Bini, et al.
Publicado: (2018)

Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells
por: Li, Miao, et al.
Publicado: (2016)

436 Examining the Role of Obesity and Leptin Signaling in Triple Negative Breast Cancer
por: Brock, Courtney, et al.
Publicado: (2022)

235 Analysiss of TNBC Cell Lines Cultured a Novel Translational Breast Cancer Microphysiological System (BC-MPS)
por: Hebert, Katherine L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lurie7om8vbkgvso348dpn1h50